
Ferrer, Leti and Oryzon to collaborate in R&D
Catalan Economy
21 Nov 2009
Pharmaceutical companies Ferrer and Leti and biotech firm Oryzon have announced the creation of the Oncochip alliance to further develop cancer research in Catalonia. Madrid-based Ingenasa and Navarra’s CIMA are also to participate in the project.
With a budget of over EUR 20 million, Oncochip will focus on the design of therapies for early diagnosis of ovarian cancer, melanoma and colon cancer. Oryzon specializes in the detection of cancer biomarkers and is already working with Reig Jofré on uterine cancer research.
Ferrer, Leti and Oryzon also plan to create a new partnership next year to develop nanotechnology projects.
Source: Expansión Cataluña 16/11/2009
More news and success stories.
-
05 May 2023
Catalonia is the second European region attracting funding for Deep Tech startups
-
02 May 2023
Catalonia's health startup ecosystem has increased investments by 87%, defying the global decline trend
-
27 Apr 2023
Barcelona will host Berry's new global center of excellence and circular innovation
-
25 Apr 2023
Barcelona will host LGT's digital development hub